S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners

Profound Medical (PROF) Stock Forecast & Price Target

$10.21
-0.74 (-6.76%)
(As of 11/28/2023 ET)
Compare
Today's Range
$9.90
$10.96
50-Day Range
$8.10
$11.18
52-Week Range
$4.50
$15.49
Volume
23,384 shs
Average Volume
24,490 shs
Market Capitalization
$218.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.75

Profound Medical Consensus Analyst Rating and Stock Price Forecast (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 3 Analyst Ratings

Analysts' Consensus Price Target

$13.75
34.67% Upside
High Forecast$20.00
Average Forecast$13.75
Low Forecast$10.00
TypeCurrent Forecast
11/29/22 to 11/29/23
1 Month Ago
10/30/22 to 10/30/23
3 Months Ago
8/31/22 to 8/31/23
1 Year Ago
11/29/21 to 11/29/22
Consensus Rating
Moderate Buy
Buy
Moderate Buy
Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
0 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
Hold
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$13.75$12.63$12.63$11.83
Predicted Upside34.67% Upside57.87% Upside41.09% Upside102.05% Upside
Get Profound Medical Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PROF and its competitors with MarketBeat's FREE daily newsletter.


PROF Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PROF Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Profound Medical Stock vs. The Competition

TypeProfound MedicalMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.67
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside34.67% Upside1,025.51% Upside2,838.32% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/28/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$11.00+0.46%
9/18/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeOutperform ➝ Strong-Buy$20.00+150.00%
3/21/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$5.50 ➝ $10.00-1.57%
1/6/2023Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$7.00 ➝ $14.00+26.58%
(Data available from 11/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












PROF Price Target - Frequently Asked Questions

What is Profound Medical's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Profound Medical stock is Moderate Buy based on the current 2 hold ratings and 1 strong buy rating for PROF. The average twelve-month price prediction for Profound Medical is $13.75 with a high price target of $20.00 and a low price target of $10.00. Learn more on PROF's analyst rating history.

Do Wall Street analysts like Profound Medical more than its competitors?

Analysts like Profound Medical less than other Medical companies. The consensus rating score for Profound Medical is 2.67 while the average consensus rating score for medical companies is 2.67. Learn more on how PROF compares to other companies.

Is Profound Medical being upgraded by Wall Street analysts?

Over the previous 90 days, Profound Medical's stock had 1 upgrade by analysts.

Does Profound Medical's stock price have much upside?

According to analysts, Profound Medical's stock has a predicted upside of 38.93% based on their 12-month stock forecasts.

What analysts cover Profound Medical?

Profound Medical has been rated by Raymond James, and Stifel Nicolaus in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:PROF) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -